Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marks move to a clinical stage company

• First subject dosed for Phase I study
• CT-1500 being developed to treat Non-24 Sleep-Wake Disorder
• Study being conducted at Nucleus Network’s Melbourne site

Oxford, 13th December 2021
Circadian Therapeutics Limited, a British company focused on the development of therapies to regulate circadian rhythms is pleased to announce the initiation of its first ever clinical programme with patient recruitment starting in their Phase I study for CT-1500 at Nucleus Network’s Melbourne site.

This marks an important milestone for Circadian Therapeutics which progresses to a clinical phase pharmaceutical company. “I am delighted at the progress the team has made to get us to this important stage in our journey,” said Dr Mark Sampson, CEO. “Circadian rhythm disruptions cause significant physical and mental morbidity and are currently under recognised and untreated. This is the first step in improving the lives of many.”

Non-24 Sleep-Wake Disorder is a serious, chronic circadian rhythm disorder very common in people who are totally blind, and it can arise at any age. Currently the treatment options for Non-24, a significant number of whom are blind veterans, are limited. Professor Shantha Rajaratnam, Chair of the Scientific Advisory Board and Deputy Director of the Turner Institute for Brain and Mental Health at Monash University, Australia, commented “ I am delighted that a new clinical programme has started for a promising treatment for Non-24. People living with this condition need effective and accessible treatment options and I look forward to seeing this progress”.

About Circadian Therapeutics
Circadian Therapeutics is a spin-out from Oxford University, specialising in the research and development of therapeutic products based on a deep understanding of the molecular control of circadian rhythms.

Contact:
contact@circadiantherapeutics.com

More information:
Mark Sampson
Mark.sampson@circadiantherapeutics.com
Lisa Stone
Lisa.stone@circadiantherapeutics.com